As of 1 February, delegates from the U.K. are no longer allowed to participate in meetings organized by the scientific communities, working parties, or management board of the European Medicines Agency (EMA).
Initially based in London, the EMA headquarters were relocated to Amsterdam after the U.K. voted to leave the European Union (EU) in June 2016.
In light of Brexit, the U.K. will no longer participate in EMA proceedings, the agency said in a statement. Contrast agent and radiopharmaceutical companies will be allowed to carry out activities in the U.K. until the Brexit transition period ends on 31 December. However, companies will need to ensure that their products comply with EU law before the end of the transition period to keep them on the EU market.
